Paramyxoviridae Infections - 25 Studies Found Completed : Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy Children : Healthy : 2006-06-27 : Biological: MEDI-534 10:4 TCID Withdrawn : DAS181 in Patients With Parainfluenza : Parainfluenza Infection : 2011-09-24 : Drug: DAS181 20 mg per day of Completed : Safety of and Immune Response to Recombinant Live-Attenuated Parainfluenza Type 1 Virus Vaccine : Parainfluenza Virus Diseases : 2008-03-05 : Biological: rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine Recruiting : A Study to Assess the Safety of Live Intranasal Sendai Virus Vaccine in Children and Toddlers : Parainfluenza Respiratory Viral Infections : 2005-09-12 : Biological: Sendai virus vaccine Enders strain; a live, unmodified intranasally administered Sendai viru Completed : Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy Adults : Hemorrhagic Fever, Ebola : 2015-09-29 : Biological: HPIV3-EbovZ GP Vaccine Administered intranasally by a VaxINator device Completed : Safety, Efficacy and Pharmacokinetics of BTA-C585 in a RSV Viral Challenge Study : Respiratory Syncytial Virus (RSV) Infection : 2016-03-21 : Drug: BTA-C585 oral capsule Ot Recruiting : Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age : Respiratory Syncytial Virus Infections : 2017-03-23 : Biological: D46/NS2/N/ΔM2-2-HindIII Recruiting : Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants and Children 6 to 24 Months of Age : Respiratory Syncytial Virus Infections : 2017-03-28 : Biological: RSV D46/NS2/N/ΔM2-2-HindIII Vaccine Active, not recruiting : A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women : Respiratory Syncytial Virus Infections : 2016-11-03 : Biological: RSV Vaccine (GSK3003891A) formulation 1 Active, not recruiting : Evaluating the Infectivity, Safety, and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants and Children 6 to 24 Months of Age : Respiratory Syncytial Virus Infections : 2016-10-31 : Biological: RSV LID ΔM2-2 1030s vaccine <<< Previous | Next >>>